💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Biocon Limited is an India-based biopharmaceutical company, engaged in the manufacture of biotechnology products and research services. The Company is in the business of manufacturing active pharmaceutical ingredients (APIs) and formulations, including biosimilar drugs for…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling, stagnant business, priced for perfection — but flagged on governance.
Biocon is scored on the pharma / healthcare framework. It keeps a thin 2.1% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 5.41× reported profit. Free cash flow is worth about -0.1% of its market value.
Over the last 3 years revenue compounded at 14%/yr and profit at -17%/yr. Book value itself has compounded 18%/yr — the hallmark of a genuine compounder. Return on equity is a weak 2.0%. In the latest quarter profit fell 31% versus the prior quarter.
At 129× earnings, the stock sits at the 88th percentile of its own 3.6-year range — the expensive end of where it has historically traded. Today's price already implies ~39%/yr earnings growth sustained for a decade — a demanding bar. The forensic screen raises a red flag: 76% of pre-tax profit is other income, not operations.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 174.64 | — | — |
| P/B | 1.71 | 4.11 | better |
| EV/EBITDA | 21.28 | 19.15 | worse |
| ROE | 1.96 | 0.68 | better |
| ROCE | 3.19 | 6.87 | worse |
| ROA | 0.52 | 1.26 | worse |
| Quick Ratio | 0.79 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 14% CAGR over 3 years — steady double-digit compounder.
Profit is on a 2-year growth streak. Revenue is outpacing profit (14% vs -17%) — costs are rising faster than the top line. The latest year saw a -74% swing — check if it's a one-off or structural.
Operating margin has compressed from 8% to 3% — costs or competition are eating into profitability.
ROE at 1% — modest; the capital isn't working hard.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. EPS outpaced profit growth — possible buybacks are concentrating earnings into fewer shares. -10% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 5.4× PAT — earnings are well-backed by cash; strong accrual quality. Investing outflows exceed operating cash — the company relies on external funding to finance expansion.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Low quarterly variance (6% spread) — a predictable, non-seasonal revenue stream.
1 of 4 quarters loss-making — quarterly profitability is uneven. Profit fell 31% QoQ — one-quarter drops can be noise, but a pattern matters.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 44.7% — dispersed ownership; institutional flows drive the stock. FIIs have accumulated for 3 straight quarters — sustained foreign institutional conviction. MF holding up 5.0pp — domestic institutional discovery underway. Both FII and MF added last quarter — broad institutional confidence.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.